Free Trial
OTCMKTS:USRM

U.S. Stem Cell (USRM) Stock Price, News & Analysis

U.S. Stem Cell logo

About U.S. Stem Cell Stock (OTCMKTS:USRM)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
778,002 shs
Market Capitalization
$70,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

Receive USRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for U.S. Stem Cell and its competitors with MarketBeat's FREE daily newsletter.

USRM Stock News Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
See More Headlines

USRM Stock Analysis - Frequently Asked Questions

U.S. Stem Cell, Inc. (OTCMKTS:USRM) released its quarterly earnings results on Wednesday, August, 7th. The company reported $0.00 EPS for the quarter. The company earned $1.30 million during the quarter.

Shares of USRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that U.S. Stem Cell investors own include Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Auxly Cannabis Group (CBWTF), EVgo (EVGO), Meta Platforms (META), Nextech3D.AI (NEXCF) and Orion Energy Systems (OESX).

Company Calendar

Last Earnings
8/07/2019
Today
11/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
OTCMKTS:USRM
Previous Symbol
NASDAQ:BHRT
Employees
11
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($0.02) per share

Miscellaneous

Free Float
550,903,000
Market Cap
$70,000.00
Optionable
Not Optionable
Beta
-1.29

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (OTCMKTS:USRM) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners